Metraipolis › archive › dc_c0eff8b52d73
Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes — Europe PMC PMID:32101536
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/32101536
- DOI
- 10.1371/journal.pcbi.1007701
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-09T09:45:05.777Z
- SHA-256 of the archived text
b6c669fae5350c8405010b5ba1375787f956b9933c451d8dcc523327f6f3b47e- Stable URL of this page
https://metraipolis.com/documento/dc_c0eff8b52d73
How to cite
Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes — Europe PMC PMID:32101536 — Europe PMC (en), https://europepmc.org/article/MED/32101536 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_c0eff8b52d73 (Metraipolis archive dc_c0eff8b52d73, sha256 b6c669fae5350c8405010b5ba1375787f956b9933c451d8dcc523327f6f3b47e)
BibTeX
@misc{dcc0eff8b52d73,
title = {Individualized genetic network analysis reveals new therapeutic vulnerabilities in 6,700 cancer genomes — Europe PMC PMID:32101536},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/32101536},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_c0eff8b52d73; sha256 b6c669fae5350c8405010b5ba1375787f956b9933c451d8dcc523327f6f3b47e},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32101536. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
Tumor-specific genomic alterations allow systematic identification of genetic interactions that promote tumorigenesis and tumor vulnerabilities, offering novel strategies for development of targeted therapies for individual patients. We develop an Individualized Network-based Co-Mutation (INCM) methodology by inspecting over 2.5 million nonsynonymous somatic mutations derived from 6,789 tumor exomes across 14 cancer types from The Cancer Genome Atlas. Our INCM analysis reveals a higher genetic interaction burden on the significantly mutated genes, experimentally validated cancer genes, chromosome regulatory factors, and DNA damage repair genes, as compared to human pan-cancer essential genes identified by CRISPR-Cas9 screenings on 324 cancer cell lines. We find that genes involved in the cancer type-specific genetic subnetworks identified by INCM are significantly enriched in established cancer pathways, and the INCM-inferred putative genetic interactions are correlated with patient survival. By analyzing drug pharmacogenomics profiles from the Genomics of Drug Sensitivity in Cancer database, we show that the network-predicted putative genetic interactions (e.g., BRCA2-TP53) are significantly correlated with sensitivity/resistance of multiple therapeutic agents. We experimentally validated that afatinib has the strongest cytotoxic activity on BT474 (IC50 = 55.5 nM, BRCA2 and TP53 co-mutant) compared to MCF7 (IC50 = 7.7 μM, both BRCA2 and TP53 wild type) and MDA-MB-231 (IC50 = 7.9 μM, BRCA2 wild type but TP53 mutant). Finally, drug-target network analysis reveals several potential druggable genetic interactions by targeting tumor vulnerabilities. This study offers a powerful network-based methodology for identification of candidate therapeutic pathways that target tumor vulnerabilities and prioritization of potential pharmacogenomics biomarkers for development of personalized cancer medicine. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PLoS computational biology, 2020 (prima pubblicazione 2020-02-26). Identificativi: PMID 32101536 · PMCID PMC7062285 · DOI 10.1371/journal.pcbi.1007701. Descrittori MeSH principali: Gene Regulatory Networks. Pagina: https://europepmc.org/article/MED/32101536 — https://doi.org/10.1371/journal.pcbi.1007701. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-09T09:40:42.927Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.